Overview
TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Status:
Recruiting
Recruiting
Trial end date:
2025-09-01
2025-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic selection device (Miltenyi Biotec).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Criteria
Inclusion Criteria:- Any patient being treated at Cincinnati Children's Hospital requiring an allogeneic
HSCT who lacks an HLA-genotypically matched related donor. Genotypically matched
related donors are allowed when there is a clinical desire to avoid the use of GVHD
prophylaxis medications.
Exclusion Criteria:
- Prior allogeneic transplant with active acute or chronic GVHD, or life-threatening
infection. Patients with a prior history of allogenic transplant without active GVHD
or life-threatening infection can be considered.